Investor Presentaiton
Key Business Performance
✓ Real-world RemsimaⓇ SC switching data has been presented at UEGW 2022
RemsimaⓇ SC
✓ Infliximab levels significantly increased post switch to RemsimaⓇ SC at 3m & remained high to 12m
✓ According to the survey, 77% of patients preferred using RemsimaⓇ SC over Infliximab IV
Infliximab PK levels of RemsimaⓇ SC switching patients
Serum infliximab levels, μg/dl
20
10
H
H
Baseline
3m
6m
12m
Patient satisfaction survey after switching to RemsimaⓇ SC
Strongly Disagree
(6%)
Disagree
(6%)
Neutral
(11%)
Strongly Agree
(53%)
Agree
(24%)
Source: Philip J Smith et al Efficacy and Safety of Elective Switching From Intravenous to Subcutaneous Infliximab (Ct-P13): A Multi-Centre Cohort Study, Journal of Crohn's and Colitis, 2022;,
jjac053, https://doi.org/10.1093/ecco-jcc/jjac053
Investor Relations 2022 10View entire presentation